

Hundred and Thirty Dollars (\$930.00) to cover the extension fee as required by 37 C.F.R.

§§1.17(a)(3) and 1.136(a).

IN THE CLAIMS:

Replace claims 1, 19, 28-30 and 38 with amended claims 1, 19, 28-30 and 38, respectively:

B1
1. (Twice amended) An oral pharmaceutical dosage form consisting essentially of a H^+ , K^+ -ATPase inhibitor, a gastric antisecretory prostaglandin analogue compound, and optional pharmaceutically acceptable excipients.

B2
19. (Twice amended) The tableted dosage form according to claim 2, wherein at least part of the tablet is in the form of an extended release formulation.

B3
28. (Twice amended) A process for the manufacture of the dosage form according to claim 3, the process comprising the steps of:
(a) preparing the H^+ , K^+ -ATPase inhibitor in the form of enteric coating layered pellets,
(b) preparing the gastric antisecretory prostaglandin analogue in the form of pellets coating layered with an extended release film,
(c) mixing the H^+ , K^+ -ATPase inhibitor pellets with the gastric antisecretory prostaglandin analogue pellets, optionally with pharmaceutically acceptable excipients, and
(d) filling the mixture into capsules.

29. (Twice amended) A process for the manufacture of the dosage form according to claim 2, the process comprising the steps of:
(a) preparing the H^+ , K^+ -ATPase inhibitor in the form of enteric coating layered pellets,

C1
33
cont

(b) mixing the H^+ , K^+ -ATPase inhibitor with pellets comprising the gastric antisecretory prostaglandin analogue, and optionally with pharmaceutically acceptable tablets excipients, and

(c) compressing the mixture into multiple unit tableted dosage forms without causing any significant change of the acid resistance of the enteric coating layered pellets.

30. (Twice amended) The process according to claim 29, wherein the pellets of the gastric antisecretory prostaglandin analogue are coating layered with an extended release layer.

C1
34

38. (Amended) The dosage form according to claim 4, wherein the dosage form further comprises a separating layer applied under the enteric coating, wherein the separating layer separates the H^+ , K^+ -ATPase inhibitor from the enteric coating layer.

✓ Add new claim 40:

35

40. An oral pharmaceutical dosage form consisting essentially of a H^+ , K^+ -ATPase inhibitor, a gastric antisecretory prostaglandin analogue compound, a calcium channel blocking agent and optional pharmaceutically acceptable excipients.